Geron Co. (NASDAQ:GERN - Get Free Report) shares saw unusually-high trading volume on Thursday . Approximately 11,157,844 shares were traded during mid-day trading, an increase of 8% from the previous session's volume of 10,309,587 shares.The stock last traded at $4.28 and had previously closed at $4.27.
Analyst Ratings Changes
Several research analysts recently commented on the company. Needham & Company LLC reissued a "buy" rating and set a $6.00 target price on shares of Geron in a research note on Friday, August 9th. Leerink Partners began coverage on shares of Geron in a research report on Monday, September 9th. They issued an "outperform" rating and a $7.00 price objective on the stock. Leerink Partnrs raised shares of Geron to a "strong-buy" rating in a research report on Monday, September 9th. Wedbush reissued an "outperform" rating and issued a $8.00 target price on shares of Geron in a report on Thursday, August 8th. Finally, HC Wainwright assumed coverage on Geron in a report on Tuesday. They set a "buy" rating and a $8.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Geron has an average rating of "Moderate Buy" and an average price target of $7.05.
Check Out Our Latest Stock Analysis on GERN
Geron Stock Performance
The firm has a fifty day simple moving average of $4.33 and a 200-day simple moving average of $4.30. The company has a current ratio of 3.61, a quick ratio of 3.60 and a debt-to-equity ratio of 0.12.
Geron (NASDAQ:GERN - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.10). Geron had a negative return on equity of 73.79% and a negative net margin of 15,990.68%. The firm had revenue of $0.88 million for the quarter, compared to the consensus estimate of $0.34 million. During the same quarter last year, the business posted ($0.09) EPS. The firm's quarterly revenue was up 2941.4% compared to the same quarter last year. Analysts predict that Geron Co. will post -0.34 earnings per share for the current year.
Hedge Funds Weigh In On Geron
A number of institutional investors have recently modified their holdings of the business. National Bank of Canada FI grew its position in Geron by 1,200.0% during the 2nd quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 6,000 shares during the last quarter. Crewe Advisors LLC boosted its stake in shares of Geron by 870.0% during the first quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 8,700 shares during the period. Kingsview Wealth Management LLC purchased a new position in shares of Geron during the first quarter worth about $34,000. American Trust acquired a new position in Geron in the 1st quarter valued at about $38,000. Finally, Rovin Capital UT ADV purchased a new stake in Geron during the 3rd quarter valued at approximately $62,000. 73.71% of the stock is owned by institutional investors and hedge funds.
About Geron
(
Get Free Report)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Geron, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.
While Geron currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
